Keratan Sulfate Enrichment Drives Nociceptor Sensitization: A Glycomic Basis for Pain Tolerance as a Biomarker of Biological Age

Jordan Richter (MD/PhD)· Mar 26, 2026

Mechanism: Age-related increase in Keratan Sulfate (KS) and decrease in Chondroitin Sulfate (CS) stiffens the extracellular matrix around nociceptors, sensitizing them to pain. Readout: Readout: This glycomic remodeling correlates with a significantly reduced Pressure Pain Threshold (PPT) and diminished Conditioned Pain Modulation (CPM).

Hypothesis

Age‑related shifts in glycosaminoglycan (GAG) sulfation—specifically an increase in keratan sulfate (KS) and a decrease in chondroitin sulfate (CS)—alter the pericellular extracellular matrix (ECM) surrounding nociceptors, lowering their activation threshold and reducing pain tolerance. This glycomic remodeling makes subjective pain sensitivity a functional readout of biological age that can outperform current epigenetic clocks.

Mechanistic Model

Fixed charge density and hydration: Loss of CS reduces negative charge and water retention, stiffening the matrix around sensory nerve endings. Increased KS adds bulky, less sulfated chains that further limit fluid flow, raising mechanical stress on embedded nociceptors.
Integrin‑mediated signaling: KS‑rich pericellular matrices favor binding of integrin α5β1 on Schwann cells, activating focal adhesion kinase (FAK) and downstream ERK pathways that increase expression of TRPV1 and TRPA1 channels, heightening mechanosensitivity.
Growth factor sequestration: CS normally sequesters TGF‑β and BMPs, keeping their activity localized. Age‑related CS loss releases these cytokines, promoting fibroblast senescence and SASP secretion (IL‑6, IL‑8) that sensitizes nearby nociceptors via JAK‑STAT signaling.
Opioid peptide diffusion: The altered GAG scaffold impedes diffusion of endogenous opioids (e.g., enkephalins) from sympathetic terminals to nociceptor terminals, reducing tonic inhibition.

These converging changes produce a lower mechanical pain threshold and reduced conditioned pain modulation (CPM) without overt tissue injury.

Experimental Design

Human cohort: Recruit participants stratified by decade (20‑30, 40‑50, 60‑70, 80+ years). Measure pressure pain threshold (PPT) and CPM using standardized algometry.
GAG profiling: Obtain minimally invasive skin punch biopsies or synovial fluid aspirates. Disaccharide composition analyzed by LC‑MS/MS to quantify KS/CS ratio and sulfation patterns (e.g., 6‑S vs 4‑S positions).
Covariates: Control for systemic inflammation (CRP, IL‑6), mitochondrial function (circulating mtDNA copy number), and vagal tone (HRV).
Statistical analysis: Test whether KS/CS ratio predicts PPT and CPM independently of age and inflammatory markers via multiple regression. Validate in an independent cohort.

Predictions and Falsifiability

Primary prediction: Higher KS/CS ratio correlates with lower PPT and diminished CPM across all age groups, with effect size comparable to or greater than established biological age clocks (e.g., GrimAge).
Secondary prediction: Pharmacological reduction of KS synthesis (using xyloside analogs) in ex vivo cultured human skin explants will restore PPT toward youthful levels.
Falsification: If KS/CS ratio shows no significant association with pain tolerance after adjusting for inflammation and mitochondrial health, the hypothesis is refuted.

This framework translates a well‑documented ECM aging signature into a measurable sensory phenotype, offering a rapid, low‑cost assay for biological aging that complements molecular clocks.

Hypothesis

Mechanistic Model

Fixed charge density and hydration: Loss of CS reduces negative charge and water retention, stiffening the matrix around sensory nerve endings. Increased KS adds bulky, less sulfated chains that further limit fluid flow, raising mechanical stress on embedded nociceptors.

Integrin‑mediated signaling: KS‑rich pericellular matrices favor binding of integrin α5β1 on Schwann cells, activating focal adhesion kinase (FAK) and downstream ERK pathways that increase expression of TRPV1 and TRPA1 channels, heightening mechanosensitivity.

Growth factor sequestration: CS normally sequesters TGF‑β and BMPs, keeping their activity localized. Age‑related CS loss releases these cytokines, promoting fibroblast senescence and SASP secretion (IL‑6, IL‑8) that sensitizes nearby nociceptors via JAK‑STAT signaling.

Opioid peptide diffusion: The altered GAG scaffold impedes diffusion of endogenous opioids (e.g., enkephalins) from sympathetic terminals to nociceptor terminals, reducing tonic inhibition.

These converging changes produce a lower mechanical pain threshold and reduced conditioned pain modulation (CPM) without overt tissue injury.

Experimental Design

Human cohort: Recruit participants stratified by decade (20‑30, 40‑50, 60‑70, 80+ years). Measure pressure pain threshold (PPT) and CPM using standardized algometry.

GAG profiling: Obtain minimally invasive skin punch biopsies or synovial fluid aspirates. Disaccharide composition analyzed by LC‑MS/MS to quantify KS/CS ratio and sulfation patterns (e.g., 6‑S vs 4‑S positions).

Covariates: Control for systemic inflammation (CRP, IL‑6), mitochondrial function (circulating mtDNA copy number), and vagal tone (HRV).

Statistical analysis: Test whether KS/CS ratio predicts PPT and CPM independently of age and inflammatory markers via multiple regression. Validate in an independent cohort.

Predictions and Falsifiability

Primary prediction: Higher KS/CS ratio correlates with lower PPT and diminished CPM across all age groups, with effect size comparable to or greater than established biological age clocks (e.g., GrimAge).

Secondary prediction: Pharmacological reduction of KS synthesis (using xyloside analogs) in ex vivo cultured human skin explants will restore PPT toward youthful levels.

Falsification: If KS/CS ratio shows no significant association with pain tolerance after adjusting for inflammation and mitochondrial health, the hypothesis is refuted.

This framework translates a well‑documented ECM aging signature into a measurable sensory phenotype, offering a rapid, low‑cost assay for biological aging that complements molecular clocks.